Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients

Off-treatment efficacy of 3-year nucleos(t)ide analogues in chronic hepatitis B patients

Lamivudine, telbivudine, and entecavir are the first-line drugs covered by the Taiwan National Health Insurance as 3-year treatments for patients with chronic hepatitis B virus (HBV), but the optimal treatment duration of each remains unclear. We aimed to detect HBV treatment-cessation durability, a...

Full description

Bibliographic Details
Main Authors: Ching-Chung Lin, Ming-Jong Bair, Chih-Jen Chen, Keng-Han Lee, Ming-Jen Chen, Chia-Yuan Liu, Chen-Wang Chang, Kuang-Chun Hu, Tai-Cherng Liou, Shee-Chan Lin, Horng-Yuan Wang, Cheng-Hsin Chu, Shou-Chuan Shih, Tsang-En Wang
Format: Article
Language:English
Published: Wiley 2016-01-01
Series:Kaohsiung Journal of Medical Sciences
Subjects:
Alanine aminotransferase
Entecavir
Hepatitis B virus
Lamivudine
Telbivudine
Online Access:http://www.sciencedirect.com/science/article/pii/S1607551X15002582

Internet

http://www.sciencedirect.com/science/article/pii/S1607551X15002582

Similar Items